AstraZeneca PLC (AZN)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 8, 2025 | $0.52 | 2025-08-08 | 2025-08-08 |
| March 24, 2025 | $1.05 | 2025-02-21 | 2025-02-21 |
| September 9, 2024 | $0.50 | 2024-08-09 | 2024-08-09 |
| March 25, 2024 | $0.98 | 2024-02-22 | 2024-02-23 |
| September 11, 2023 | $0.47 | 2023-08-10 | 2023-08-11 |
Dividends Summary
- AstraZeneca PLC has issued 45 dividend payments over the past 22 years
- The most recent dividend was paid 12 days ago, on September 8, 2025
- The highest dividend payed out to investors during this period was $1.95 per share
- The average dividend paid during this period was $0.88 per share.
Company News
Japan's auto-injectors market for GLP-1 receptor agonists is projected to grow from $137.7 million in 2025 to $292.9 million by 2038, driven by rising type 2 diabetes and obesity cases, and increasing demand for convenient at-home medication delivery methods.
AstraZeneca reported mixed results in clinical trials: Fasenra did not meet primary endpoint for COPD, while Saphnelo showed significant reduction in lupus disease activity in a Phase 3 trial.
Two healthcare stocks, Precigen and Mineralys Therapeutics, have seen significant stock price increases recently due to FDA approval and promising clinical trial results in rare disease treatment and hypertension medication development.
AstraZeneca reported strong Q2 results, beating estimates for earnings and sales. The company's key drugs like Tagrisso, Ultomiris, Farxiga, and Calquence performed well, while Lynparza and Imfinzi sales were slightly weak. AstraZeneca raised its sales and earnings growth expectations for the year, citing a strong first-half performance.
Morgan Stanley maintains an Overweight rating and GBP145.00 price target on AstraZeneca, expecting the company's revenue growth to remain robust, with potential for an upward revision to its full-year 2024 guidance.